Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-Containing Treatment.

Trial Profile

Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-Containing Treatment.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Additional lead trial centres and investigator identified as reported by ClinicalTrials.gov, last updated 9 Mar 2009
    • 09 Mar 2009 Primary endpoint identified as disease free survival as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top